KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Minority Interest (2021 - 2025)

Adaptive Biotechnologies' Minority Interest history spans 5 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Minority Interest rose 2871.43% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 2871.43%, while the annual FY2025 figure was $6.2 million, 2871.43% up from the prior year.
  • Minority Interest for Q4 2025 was $6.2 million at Adaptive Biotechnologies, up from -$182000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $6.2 million in Q4 2025 and bottomed at -$224000.0 in Q4 2024.
  • The 5-year median for Minority Interest is -$68500.0 (2023), against an average of $245900.0.
  • The largest annual shift saw Minority Interest crashed 675.0% in 2023 before it soared 2871.43% in 2025.
  • A 5-year view of Minority Interest shows it stood at $110000.0 in 2021, then plummeted by 160.91% to -$67000.0 in 2022, then crashed by 80.6% to -$121000.0 in 2023, then crashed by 85.12% to -$224000.0 in 2024, then skyrocketed by 2871.43% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Minority Interest are $6.2 million (Q4 2025), -$182000.0 (Q3 2025), and -$181000.0 (Q2 2025).